**Adiposity and Heart Failure: How to Manage?**

**Dr. Nikita Pal**

Doctoral Research Scholar, Department of Pharmacy Practice

JSS College of Pharmacy, Mysuru, Karnataka.

**Introduction:**

Adiposity, commonly referred to as excessive body fat or obesity, has reached alarming levels worldwide. It is a complex metabolic disorder associated with various adverse health consequences, including an increased risk of cardiovascular diseases. While obesity is commonly defined using anthropometric measures such as body mass index (BMI), waist circumference, and waist-to-hip ratio, waist circumference-to-BMI ratio, the detrimental cardiovascular effects of obesity may be attributed to the specific distribution of excess fat rather than just the overall accumulation. 1, 2

Among these, heart failure, a condition characterized by the heart's inability to pump blood effectively, stands out as a significant concern. Adiposity and heart failure has garnered substantial attention in recent years, as evidence suggests that excess adipose tissue can contribute to the development and progression of heart failure through multiple mechanisms. The prevalence of heart failure with preserved ejection fraction (HFpEF) has significantly increased in recent years, now accounting for approximately 50% of all heart failure (HF) cases. Central adiposity, specifically, has been found to have a direct correlation with increased stiffness of the left ventricle, contributing to diastolic dysfunction observed in HFpEF. Additionally, certain studies have demonstrated that obesity, as defined by BMI, is associated with a higher risk of HFpEF but not with heart failure with reduced ejection fraction (HFrEF).  3, 4

The prevalence of both adiposity and heart failure has risen dramatically in recent decades, posing a significant public health challenge. The burden of these conditions extends beyond individual health, impacting healthcare systems, economies, and quality of life. Understanding the intricate relationship between adiposity and heart failure is crucial for developing effective prevention and management strategies that can alleviate the burden of these conditions on individuals and society.

The purpose of this chapter is to delve into the relationship between adiposity and heart failure, examining the underlying mechanisms, clinical implications, and management approaches. By comprehensively exploring this topic, we aim to provide healthcare professionals, researchers, and students with a deeper understanding of the interplay between adiposity and heart failure and equip them with the knowledge necessary to optimize patient care.

Throughout this chapter, we will discuss the epidemiology and prevalence of adiposity-related heart failure, the mechanisms by which adiposity contributes to the pathogenesis of heart failure, the clinical presentation and diagnosis of adiposity-related heart failure, and the associated risk factors and comorbidities. We will also delve into lifestyle modifications, dietary strategies, exercise guidelines, pharmacological interventions, and surgical procedures employed in the management of adiposity-related heart failure. Additionally, psychosocial considerations, patient education, and long-term care will be explored to provide a comprehensive approach to managing this complex condition.

By addressing the challenges posed by adiposity-related heart failure and implementing effective management strategies, we can strive towards better outcomes for patients, reducing the burden on healthcare systems, and ultimately improving the overall health and well-being of individuals affected by this condition.

**Relationship between Adiposity and Heart Failure:**

The relationship between adiposity and heart failure is a complex and multifaceted one, with numerous mechanisms and pathways at play. Adiposity and heart failure share common pathophysiological pathways, including chronic inflammation, oxidative stress, insulin resistance, and hormonal dysregulation, such as increased levels of leptin and decreased levels of adiponectin, which can further impact cardiovascular health and cardiac function. Adipose tissue, especially visceral adipose tissue (VAT) produces and releases various bioactive substances known as adipokines. VAT exhibits distinct relationships with cardiometabolic risk factors compared to adipose tissue located in other compartments, such as subcutaneous adipose tissue (SAT). 1, 5 In individuals with obesity and coronary artery disease, it seems that the distribution of fat within the body, rather than the BMI alone, is more closely linked to mortality outcomes. Moreover, adiposity is associated with an increased prevalence of other risk factors for heart failure, such as hypertension, dyslipidemia, and type 2 diabetes mellitus, and multiple comorbidities, further exacerbating the risk. 6 These comorbidities often coexist with adiposity and act synergistically to further increase the risk of heart failure. The clustering of these risk factors in individuals with adiposity contributes to the development of a distinct subtype of heart failure known as obesity-related heart failure.

In addition to the metabolic and inflammatory factors, adipokines also exerts mechanical effects on the cardiovascular system. The increased adipose tissue mass in obese individuals places additional stress on the heart, leading to increased cardiac workload. This can result in structural changes, such as left ventricular hypertrophy, and impairments in cardiac function, ultimately leading to heart failure. It is worth noting that the relationship between adiposity and heart failure is not uniform across all types of heart failure. While adiposity, as defined by BMI, and other anthropometric parameters has been associated with a greater risk for heart failure with preserved ejection fraction (HFpEF), the evidence for its association with heart failure with reduced ejection fraction (HFrEF) is less clear. This suggests that the mechanisms linking adiposity and heart failure may differ depending on the underlying subtype of heart failure. 7

**Epidemiology and Prevalence of Adiposity-Related Heart Failure:**

The prevalence of this condition has been steadily increasing over the past few decades, mirroring the global obesity epidemic. Adiposity-related heart failure poses a significant burden on public health systems worldwide, leading to increased morbidity, mortality, and healthcare costs. Data from various epidemiological studies provide valuable insights into the prevalence and impact of adiposity-related heart failure. According to the World Health Organization (WHO), more than 1.9 billion adults were overweight in 2016, with over 650 million classified as obese. These numbers are projected to rise further if effective interventions are not implemented. According to 2020 census, 39 million children under the age of 5 were found to be overweight or obese. 8, 9

Research has shown a clear association between obesity and heart failure. A large-scale study conducted in the United States, known as the Framingham Heart Study, demonstrated that the risk of heart failure increases 5% in men and 7% in women per 1 kg/m2 with higher body mass index (BMI). Individuals with a BMI greater than 30 kg/m² had a significantly elevated double risk of developing heart failure compared to those within the normal weight range. 10

Furthermore, adiposity-related heart failure tends to affect younger individuals compared to heart failure unrelated to obesity. A study published in the Journal of the American College of Cardiology found that obese individuals in their 40s had a 70% higher risk of developing heart failure compared to their non-obese counterparts. This highlights the importance of addressing obesity as a modifiable risk factor for heart failure, especially in younger populations. 11

The impact of adiposity-related heart failure on mortality rates is also substantial. A systematic review and meta-analysis conducted by the American Heart Association (AHA) revealed that obesity increased the risk of heart failure-related mortality by approximately 30%. Moreover, obesity-related heart failure has been associated with worse outcomes, including higher rates of hospitalization and reduced quality of life. 12

To address the rising prevalence of adiposity-related heart failure, comprehensive strategies are needed. These strategies should focus on both prevention and management, targeting the underlying causes of obesity and promoting a healthy lifestyle. Implementing population-wide interventions, such as promoting regular physical activity, improving dietary habits, and providing access to weight management programs, can play a crucial role in reducing the burden of adiposity-related heart failure.

The epidemiological data clearly demonstrate the increasing prevalence and impact of adiposity-related heart failure. Obesity is a significant risk factor for heart failure, particularly in younger individuals. The rising rates of obesity worldwide necessitate urgent action to prevent and manage adiposity-related heart failure through comprehensive public health strategies. By addressing the underlying causes of obesity and promoting a healthy lifestyle, it is possible to mitigate the burden of this condition and improve cardiovascular health on a global scale.

**Mechanisms of Adiposity-Induced Heart Failure:**

Adiposity-induced heart failure involves a complex interplay of various physiological and pathological mechanisms. One of the key mechanisms linking adiposity to heart failure is the chronic low-grade inflammation observed in obesity. 13

***Chronic Inflammation:***

Chronic inflammation is a prominent feature of obesity and plays a crucial role in the pathogenesis of adiposity-induced heart failure. Adipose tissue, especially visceral adipose tissue, releases pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). These cytokines contribute to systemic inflammation and can directly affect the heart. They promote myocardial inflammation, fibrosis, and hypertrophy, leading to adverse cardiac remodelling. Inflammatory cells, including macrophages and lymphocytes, infiltrate the myocardium and further perpetuate the inflammatory response, exacerbating cardiac dysfunction.

***Insulin Resistance:***

Insulin resistance, a hallmark of obesity, is characterized by impaired insulin signalling and reduced glucose uptake in target tissues. In the context of the heart, insulin resistance disrupts glucose metabolism and alters substrate utilization. As a compensatory response, the heart increases its reliance on fatty acid oxidation as a source of energy. However, this shift towards increased fatty acid utilization can have detrimental effects. The excessive delivery and utilization of fatty acids in the myocardium can lead to the accumulation of toxic lipid metabolites, known as lipotoxicity. Lipotoxicity impairs mitochondrial function, promotes oxidative stress, and induces cellular damage. Additionally, the impaired utilization of glucose as an energy source compromises cardiac efficiency and contractility, contributing to the development of heart failure.

***Oxidative Stress:***

Oxidative stress, characterized by an imbalance between the production of reactive oxygen species (ROS) and the antioxidant defence system, is another important mechanism in adiposity-induced heart failure. Adipose tissue, particularly dysfunctional adipocytes, generates increased levels of ROS in obesity. Elevated ROS production overwhelms the antioxidant defence mechanisms, leading to oxidative stress. The excessive ROS can directly damage cardiac cells, promote inflammation, and contribute to myocardial fibrosis. Oxidative stress also affects intracellular signalling pathways involved in cardiac remodelling and contractile dysfunction. Furthermore, oxidative stress disrupts nitric oxide signalling, impairing vasodilation and leading to endothelial dysfunction, which further exacerbates cardiac dysfunction.

***Imbalance of Adipokines Production:***

Dysregulated production of adipokines, bioactive molecules secreted by adipose tissue, is another mechanism involved in adiposity-induced heart failure. Adipokines such as adiponectin, leptin, and resistin exert both local and systemic effects. Adiponectin, which has anti-inflammatory and insulin-sensitizing properties, is often reduced in obesity. Reduced adiponectin levels are associated with adverse cardiac remodelling, inflammation, and impaired cardiac contractility. Leptin, a hormone involved in appetite regulation, is increased in obesity. Elevated leptin levels contribute to the development of insulin resistance, promote cardiac hypertrophy and fibrosis, and impair cardiac function. Resistin, another adipokine, has been linked to inflammation and insulin resistance and may contribute to cardiac dysfunction in obesity.

**Clinical Presentation and Diagnosis of Adiposity-Related Heart Failure:**

The clinical presentation of adiposity-related heart failure shares similarities with heart failure of other etiologies. Patients often experience symptoms such as dyspnea (shortness of breath), especially paroxysomal nocturnal dyspnea (PND), fatigue, exercise intolerance, orthopnea (difficulty breathing while lying flat), and pedal edema (swelling of the feet and ankles). These symptoms can be attributed to the impaired cardiac function, fluid retention, and pulmonary congestion commonly observed in heart failure. 1, 14

However, adiposity-related heart failure may exhibit some unique characteristics. Obese individuals with heart failure tend to have a higher prevalence of preserved ejection fraction (HFpEF), also known as diastolic heart failure. This occurs when the heart's ability to relax and fill properly is impaired, leading to elevated pressures within the heart. Patients with HFpEF may exhibit symptoms of heart failure despite having a relatively normal left ventricular ejection fraction (LVEF). 15

In addition to the typical symptoms of heart failure, obesity-related heart failure can also manifest with symptoms related to obesity itself. These may include excessive weight gain, snoring, daytime sleepiness, and symptoms of obstructive sleep apnea (OSA). Obesity-related sleep-disordered breathing, such as sleep apnea, is common in this population and can contribute to the development and worsening of heart failure symptoms. 15

The diagnosis of adiposity-related heart failure involves a combination of clinical evaluation, imaging studies, and laboratory tests. The initial assessment includes a thorough medical history, physical examination, and evaluation of cardiovascular risk factors. 16 The healthcare provider may inquire about the patient's weight history, dietary habits, exercise routine, and any prior history of heart disease or other comorbidities.

***2D-Echocardiography:***

Imaging studies play a crucial role in the diagnosis of heart failure. Echocardiography is typically performed to assess cardiac structure and function. It provides information about ventricular dimensions, wall thickness, ejection fraction, and the presence of any valvular abnormalities. In cases of HFpEF, echocardiography helps evaluate diastolic function and assess for signs of elevated left ventricular filling pressures.

***Cardiac Imaging Tests:***

Additional imaging modalities, such as cardiac magnetic resonance imaging (MRI) or computed tomography (CT), may be utilized to further evaluate cardiac structure and function, particularly in cases where there is uncertainty or the need for more detailed anatomical information.

***Laboratory Investigations:***

Laboratory tests are important in assessing cardiac biomarkers and identifying potential underlying comorbidities. Blood tests may include measurement of brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP), which are released by the heart in response to increased cardiac wall stress. Elevated levels of these biomarkers are indicative of heart failure.

Furthermore, assessing comorbidities commonly associated with obesity, such as hypertension, diabetes, dyslipidemia, and renal dysfunction, is essential for a comprehensive evaluation. These conditions can contribute to the development and progression of heart failure and may require additional management strategies.

**Risk Factors and Co-morbidities Associated with Adiposity and Heart Failure:**

Adiposity, or obesity, is a complex condition associated with a multitude of risk factors and co-morbidities that significantly increase the likelihood of developing heart failure. 17

***Cardiovascular Risk Factors:***

Obesity is often accompanied by a cluster of cardiovascular risk factors, including hypertension, dyslipidemia, and insulin resistance. These factors contribute to the development of atherosclerosis, endothelial dysfunction, and increased cardiac workload, increasing the risk of heart failure. Hypertension, in particular, is highly prevalent in obese individuals and plays a central role in the development of obesity-related heart failure by promoting left ventricular hypertrophy and impairing diastolic function.

***Diabetes Mellitus:***

Obesity and type 2 diabetes are closely linked, and the presence of diabetes further amplifies the risk of heart failure in obese individuals. Insulin resistance, a hallmark of obesity, is a major contributing factor to the development of type 2 diabetes. Diabetes itself leads to structural and functional changes in the heart, including myocardial fibrosis and impaired cardiac contractility. The combination of obesity and diabetes creates a synergistic effect, accelerating the progression of heart failure.

***Metabolic Syndrome:***

Metabolic syndrome is a cluster of metabolic abnormalities that often coexist with obesity. It includes a combination of central obesity, dyslipidemia, hypertension, and impaired glucose metabolism. Metabolic syndrome significantly increases the risk of developing heart failure, as each component of the syndrome independently contributes to adverse cardiac remodelling, myocardial dysfunction, and the development of coronary artery disease.

***Sleep Apnoea and Respiratory Disorders:***

Obesity is a major risk factor for sleep-disordered breathing, particularly obstructive sleep apnoea. Sleep apnoea is characterized by recurrent episodes of upper airway collapse during sleep, leading to interrupted breathing and oxygen desaturation. The intermittent hypoxia and increased sympathetic activation associated with sleep apnoea contribute to systemic inflammation, oxidative stress, and endothelial dysfunction, all of which can impact cardiac structure and function. Sleep apnoea has been strongly associated with the development and progression of heart failure.

***Chronic Kidney Disease:***

Obesity is a risk factor for the development and progression of chronic kidney disease (CKD). CKD and obesity share common pathophysiological mechanisms, including inflammation, oxidative stress, and endothelial dysfunction. CKD is an independent risk factor for heart failure, and the presence of obesity further exacerbates this risk. The combination of CKD and obesity creates a vicious cycle, as impaired renal function can contribute to fluid retention and worsen heart failure symptoms. Moreover, CKD and anaemia have a closer association due to multiple factors such as decreased production of erythropoietin, iron deficiency, chronic inflammation, and increased red blood cells destructions.

***Psychological and Psychiatric Disorders:***

Obesity is often associated with psychological and psychiatric disorders, such as depression, anxiety, and eating disorders. These conditions can contribute to poor adherence to lifestyle modifications, medication non-compliance, and reduced engagement in cardiac rehabilitation programs. Furthermore, psychological stressors and emotional factors associated with these disorders can have a direct impact on cardiac function and contribute to the development and progression of heart failure. 18

**Lifestyle Modifications for Managing Adiposity and Heart Failure:**

Adopting healthy lifestyle habits is a cornerstone of managing adiposity-related heart failure. Lifestyle modifications aim to address both adiposity (obesity) and heart failure by promoting weight loss, improving cardiovascular health, and reducing the burden on the heart. The following lifestyle modifications are recommended for individuals with adiposity-related heart failure 19, 20:

***Healthy Diet:*** A balanced and nutritious diet plays a crucial role in managing adiposity and heart failure. Key dietary recommendations include:

* **Calorie restriction:** Achieving and maintaining a healthy body weight is essential. Caloric intake should be adjusted to promote gradual, sustainable weight loss, if necessary.
* **Macronutrient composition:** Emphasize a diet rich in fruits, vegetables, whole grains, and lean protein sources while limiting saturated and trans fats, cholesterol, and sodium.
* **Portion control:** Monitoring portion sizes can help manage caloric intake and prevent overeating.
* **Heart-healthy fats:** Incorporate sources of unsaturated fats, such as nuts, seeds, avocados, and fatty fish, which provide essential omega-3 fatty acids.
* **Sodium restriction:** It is crucial for managing fluid retention and reducing the strain on the heart. Limiting sodium intake can help control blood pressure and decrease the risk of fluid overload. It is recommended to reduce the consumption of processed and packaged foods, which tend to be high in sodium.
* **Fluid restriction:** In advanced heart failure cases with fluid retention, fluid intake may need to be restricted. However, individualized guidance from a healthcare professional is essential.

***Regular Physical Activity:*** Regular exercise is important for managing both adiposity and heart failure. Physical activity offers numerous benefits, including weight management, improved cardiovascular fitness, enhanced muscle strength, and overall well-being. It is recommended to engage in moderate-intensity aerobic exercise, such as brisk walking, cycling, or swimming, for at least 150 minutes per week, or as advised by a healthcare professional. Additionally, incorporating strength training exercises to improve muscle tone and strength is beneficial. Exercise plans should be tailored to individual capabilities and preferences, with gradual progression and regular monitoring.

***Smoking Cessation:*** Smoking is a major risk factor for cardiovascular disease, including heart failure. Quitting smoking is vital for improving heart health and overall well-being. Support from healthcare professionals, smoking cessation programs, and nicotine replacement therapies can aid in smoking cessation efforts.

***Weight Management:*** Achieving and maintaining a healthy weight is an essential component of managing adiposity-related heart failure. Weight loss strategies should be individualized and incorporate a combination of dietary changes, increased physical activity, and behavioral modifications. Aiming for a gradual weight loss of 1-2 pounds per week is generally considered safe and sustainable.

**Medication Adherence:** Strict adherence to guidelines-directed four-pillar prescribed medications is crucial in managing heart failure. Medications prescribed for heart failure, such as beta-blockers, ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, and aldosterone antagonists, play a vital role in improving heart function and reducing symptoms. It is important to follow the medication regimen as prescribed, and any concerns or side effects should be promptly discussed with a healthcare professional.

**Stress Management:** Managing stress is beneficial for overall cardiovascular health. Chronic stress can contribute to the progression of heart failure. Adopting stress management techniques, such as relaxation exercises, mindfulness, meditation, and engaging in enjoyable activities, can help reduce stress levels and promote emotional well-being.

**Regular Medical Monitoring:** Routine medical follow-up is essential for monitoring progress, adjusting treatment plans, and addressing any emerging concerns. Regular check-ups, including measurements of weight, blood pressure, and laboratory tests, are necessary to track cardiovascular health and make informed decisions regarding medications and lifestyle modifications.

It is important to note that lifestyle modifications should be personalized to individual needs and abilities. Collaborating with healthcare professionals, including cardiologists, dietitians, and exercise specialists, can provide guidance, support, and tailored recommendations to optimize the management of adiposity-related heart failure.

**Pharmacological Management of Adiposity and Heart Failure:**

The pharmacological management of adiposity-related heart failure focuses on addressing both the underlying heart failure and managing adiposity (obesity). The specific guideline directed medical treatment (GDMT) approach may vary depending on the severity of heart failure, symptoms, and individual patient characteristics. Here are some common pharmacological interventions used in the management of adiposity-related heart failure: 16, 21

***Angiotensin-Converting Enzyme (ACE) Inhibitors:*** ACE inhibitors are commonly prescribed medications for heart failure. They block the conversion of angiotensin I to angiotensin II, a hormone that causes vasoconstriction and increases fluid retention. By inhibiting this pathway, ACE inhibitors improve symptoms, decrease fluid retention, and reduce the workload on the heart. They may also have beneficial effects on cardiac remodelling. Examples of ACE inhibitors include lisinopril, enalapril, and ramipril.

***Angiotensin Receptor Blockers (ARBs):*** ARBs work by blocking the action of angiotensin II at the receptor level. Like ACE inhibitors, ARBs help reduce vasoconstriction, improve symptoms, and decrease fluid retention in heart failure. They are often prescribed as an alternative to ACE inhibitors in patients who cannot tolerate the latter. Examples of ARBs include losartan, valsartan, and candesartan.

**Beta-Blockers:** Beta-blockers are medications that block the effects of adrenaline and noradrenaline on the heart. They help lower heart rate, reduce blood pressure, and decrease the workload on the heart. Beta-blockers are effective in managing symptoms, improving cardiac function, and reducing the risk of heart failure progression. Examples of beta-blockers commonly used in heart failure management include carvedilol, metoprolol succinate, and bisoprolol.

***Diuretics:*** Diuretics help reduce fluid accumulation and relieve symptoms of fluid overload, such as edema and shortness of breath. They work by increasing urine production and promoting the excretion of excess fluid and sodium from the body. Diuretics are often used in heart failure management, particularly in cases of fluid retention. Examples of diuretics include furosemide, hydrochlorothiazide, and spironolactone.

***Mineralocorticoid Receptor Antagonists (MRAs):*** MRAs, such as spironolactone and eplerenone, block the effects of aldosterone, a hormone that promotes fluid retention and cardiac remodelling. By blocking aldosterone, MRAs reduce fluid retention, prevent potassium loss, and have shown to improve outcomes in patients with heart failure.

***Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors:*** SGLT2 inhibitors, initially developed for the treatment of diabetes, have emerged as a promising class of medications for heart failure management and also considered as a safer drug in CKD. They work by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. SGLT2 inhibitors have demonstrated beneficial effects in reducing heart failure hospitalizations and improving cardiovascular outcomes in patients with heart failure, including those with or without diabetes. Examples of SGLT2 inhibitors include empagliflozin, dapagliflozin, and canagliflozin.

***Other Medications:*** Additional medications may be prescribed based on individual patient needs and comorbidities. These may include aldosterone antagonists, digoxin (for certain cases of heart failure), ivabradine (to reduce heart rate), and antiplatelet or anticoagulant agents if there is a concurrent risk of blood clots or cardiovascular events.

Medication management should be personalized to the patient's specific condition and guided by healthcare professionals, such as cardiologists or heart failure specialists. Regular follow-up appointments and monitoring are crucial to assess medication effectiveness, adjust dosages, manage potential side effects, and optimize the pharmacological treatment of adiposity-related heart failure.

**Surgical Interventions and Procedures for Adiposity-Related Heart Failure:**

Surgical interventions and procedures may be considered in the management of adiposity-related heart failure, particularly in cases where conservative measures and pharmacological treatments have not provided adequate improvement or in selected patients with specific indications. Here are some surgical interventions and procedures that may be used: 22

***Bariatric Surgery:*** Bariatric surgery is a weight-loss procedure that involves modifying the gastrointestinal tract to promote significant and sustained weight loss in individuals with severe obesity. It is generally reserved for patients with a body mass index (BMI) of 40 or higher or those with a BMI of 35-39.9 who have obesity-related comorbidities, including heart failure. Bariatric surgery can lead to substantial weight loss, improvement in metabolic parameters, and a reduction in cardiovascular risk factors. This, in turn, may have a positive impact on heart failure symptoms and overall cardiac function.

***Percutaneous Coronary Intervention (PCI):*** PCI, also known as coronary angioplasty, is a minimally invasive procedure performed to open narrowed or blocked coronary arteries. It involves inserting a catheter with a balloon at the tip into the affected artery and inflating the balloon to widen the artery and restore blood flow. In some cases, a stent may be placed to keep the artery open. PCI is commonly performed in individuals with coronary artery disease, which often coexists with adiposity-related heart failure. By improving blood flow to the heart muscle, PCI can relieve symptoms and improve cardiac function in these patients.

***Left Ventricular Assist Devices (LVADs):*** LVADs are mechanical devices implanted in the chest that help the heart pump blood effectively. They are typically used in patients with advanced heart failure who have not responded to other treatments or as a bridge to heart transplantation. LVADs can temporarily support the failing heart or be used as a long-term solution in patients who are not eligible for transplantation. These devices can significantly improve heart function, relieve symptoms, and improve quality of life in patients with adiposity-related heart failure.

***Heart Transplantation:*** Heart transplantation may be considered in patients with end-stage heart failure who have not responded to other therapies. It involves replacing the patient's failing heart with a healthy heart from a deceased donor. Heart transplantation can provide a new lease on life for individuals with severe heart failure, including those with adiposity-related heart failure. However, transplantation is typically reserved for patients who meet specific eligibility criteria and have undergone careful evaluation.

**Future Directions and Emerging Therapies in Adiposity and Heart Failure Management:**

Continued research, advancements in technology, and a comprehensive and individualized approach to care are essential to address the underlying adiposity, optimizes cardiovascular outcomes for individuals with adiposity-associated heart failure. Precision medicines, pharmacological interventions such as, novel drug targets, metabolic modulators, anti-inflammatory therapies, device-based therapies, telemedicine and digital health technologies, lifestyle interventions, multi-disciplinary care approach, and public health initiatives are subject to ongoing research and development, and their clinical implementation will require rigorous evaluation and validation.

**References:**

1. Rao VN, Zhao D, Allison MA, Guallar E, Sharma K, Criqui MH, Cushman M, Blumenthal RS, Michos ED. Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). JACC: Heart Failure. 2018 Dec;6(12):999-1007.
2. Mahmoud I, Al-Wandi AS, Gharaibeh SS, Mohamed SA. Concordances and correlations between anthropometric indices of obesity: a systematic review. Public Health. 2021 Sep 1; 198:301-6.
3. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. *Circ Res* 2014; 115:79–96.
4. Ho JE, Lyass A, Lee DS et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. *Circ Heart Fail* 2013; 6:279–86.
5. Narumi H, Yoshida K, Hashimoto N et al. Increased subcutaneous fat accumulation has a protective role against subclinical atherosclerosis in asymptomatic subjects undergoing general health screening. *Int J Cardiol* 2009; 135:150–5.
6. Bays HE. Adiposopathy is “sick fat” a cardiovascular disease? *Journal of the American College of Cardiology* 2011; 57:2461–73.
7. Suthahar N, Meems LM, Withaar C, Gorter TM, Kieneker LM, Gansevoort RT, Bakker SJ, van Veldhuisen DJ, de Boer RA. Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVEND. Scientific reports. 2022 Jan 7;12(1):147.
8. Pugliese G, Liccardi A, Graziadio C, Barrea L, Muscogiuri G, Colao A. Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. International Journal of Obesity. 2022 Mar;46(3):449-65.
9. World Health Organization (WHO). Obesity and Overweight. 2021. Retrieved from: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.
10. Levitan EB, Yang AZ, Wolk A, Mittleman MA. Adiposity and incidence of heart failure hospitalization and mortality: a population-based prospective study. Circulation: Heart Failure. 2009 May 1;2(3):202-8.
11. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. Journal of the American College of Cardiology. 2020 Dec 22;76(25):2982-3021.
12. Rich JD, Burns J, Freed BH, Maurer MS, Burkhoff D, Shah SJ. Meta‐Analysis Global Group in Chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction. Journal of the American Heart Association. 2018 Oct 16;7(20): e009594.
13. Ebong IA, Goff Jr DC, Rodriguez CJ, Chen H, Bertoni AG. Mechanisms of heart failure in obesity. Obesity research & clinical practice. 2014 Nov 1;8(6): e540-8.
14. Mishra S, Mohan JC, Nair T, Chopra VK, Harikrishnan S, Guha S, Ramakrishnan S, Ray S, Sethi R, Samal UC, Chandra KS. Management protocols for chronic heart failure in India. Indian heart journal. 2018 Jan 1;70(1):105-27.
15. Borlaug BA, Jensen MD, Kitzman DW, Lam CS, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovascular research. 2022 Dec 7;118(18):3434-50.
16. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. ESC Clinical Practice Guidelines. European Society of Cardiology. 2021. Retrieved from: <https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure>.
17. Pazos F. Range of adiposity and cardiorenal syndrome. World Journal of Diabetes. 2020 Aug 8;11(8):322.
18. Sarwer DB, Polonsky HM. The psychosocial burden of obesity. Endocrinology and Metabolism Clinics. 2016 Sep 1;45(3):677-88.
19. Bremner JD, Moazzami K, Wittbrodt MT, Nye JA, Lima BB, Gillespie CF, Rapaport MH, Pearce BD, Shah AJ, Vaccarino V. Diet, stress and mental health. Nutrients. 2020 Aug 13;12(8):2428.
20. Lifestyle changes for heart failure. American Heart Association. Retrieved from: <https://www.heart.org/en/health-topics/heart-failure/treatment-options-for-heart-failure/lifestyle-changes-for-heart-failure#:~:text=Following%20recommendations%20about%20diet%2C%20exercise%20and%20other%20habits,lifestyle%20changes%20can%20be%20easier%20said%20than%20done>.
21. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022 May 3;79(17): e263-421.
22. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21): e984-1010.